Phase 1/2Recruiting
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
MC240502: Cancer CARE (Connected Access and Remote Expertise) Beyond Walls In-home iNtraVesIcal ThErapy (INVITE) Study - A Phase Ib/II, Single-Arm Trial of Delivering Intravesical Therapy for Bladder Cancer in Patients' Homes
- Sponsor
- Mayo Clinic (Academic or other)
- Enrollment
- 40 planned
- Conditions
- Non-Muscle Invasive Bladder Carcinoma; Stage 0a Bladder Cancer AJCC v8; Stage I Bladder Cancer AJCC v8; Stage 0is Bladder Cancer AJCC v8
- Interventions
- BCG Solution; Cystoscopy; Docetaxel; Gemcitabine; Home Health Encounter; Mitomycin; Questionnaire Administration
- Ages
- adults, older adults
- Registry
- NCT06704191
Full record on ClinicalTrials.gov
From the registry
This phase Ib/II trial compares the safety, tolerability and acceptability of intravesical chemotherapy given at home to in-clinic administration in patients with non-muscle invasive bladder cancer. Chemotherapy drugs, such as bacillus Calmette-Guerin (BCG), gemcitabine, docetaxel, and mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Standard of care chemotherapy for non-invasive bladder cancer is usually given directly into the bladder through a catheter (intravesical). This process requires numerous visits and can be disruptive to the lives of patients and caregivers. Bringing cancer care to the patients with in-home intravesical therapy may help reduce the disruption to daily lives. In-home intravesical chemotherapy may be safe and tolerable and may also be preferable to in-clinic administration in patients with non-muscle invasive bladder cancer.
Primary outcomes
- Incidence and severity of adverse events (AEs)
- Feasibility of in-home intravesical therapy
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered